CAR T-Cell Therapy

Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point

August 04, 2020

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.

CAR T Cell Agents Show Variance in Different Lymphoma Subtypes

July 08, 2020

Chimeric antigen receptor T-cell therapy when administered to patients with non-follicular low-grade lymphoma may experience different efficacy outcomes than patients with aggressive B-cell lymphomas, according to a single-institution retrospective data.